children with CKD has not been established, again mainly due to the absence of consensus regarding the diagnosis of these nutritional disorders.
The pathophysiology of PEW/cachexia syndrome in CKD is multifactorial. BThe proposed criteria to establish the diagnosis of PEW includes four categories: (1) biochemical indexes; (2) body weight parameters, including reduced body fat and weight loss; (3) reduced muscle mass; (4) low protein/energy intake [ 2] . Anorexia is included as a criterion for cachexia [7] , while poor protein/energy intake is a criterion for PEW [1] . Anorexia, defined as the loss of appetite and early satiety, is prevalent in adults and pediatric CKD patients [8] . Anorexia in these patients is multifactorial, including an abnormal sense of taste, abnormal gastric emptying, and increased circulatory inflammatory cytokines [2, 9] . Perturbations in anorexigenic/ orexigenic hormones, including leptin, ghrelin, and obestatin, may also be important [10] .
Ghrelin and obestatin
Ghrelin is synthesized and secreted predominantly by the stomach, but also by many other tissues. It has hormonal as well as autocrine/paracrine effects [11] . The GHRL gene encodes human ghrelin. Transcription produces a prepro-peptide that undergoes acylation by the ghrelin O-acyltransferase (GOAT) enzyme and subsequent modification by convertases, resulting in acylated ghrelin (AG) or unacylated ghrelin (UAG) [12] . Recent investigations show that prepro-ghrelin mRNA may also be involved in the synthesis of obestatin, whose physiological effects diverge from those of ghrelin [13] .
In humans, circulating ghrelin consists of UAG (>90%), AG, and C-ghrelin. The acylated form of ghrelin has been considered to be the primary appetite-stimulating hormone while UAG induces negative energy balance [14] . There is evidence from rodent studies that obestatin is anorexigenic, by inducing anorexia and weight loss as well as slowing peristalsis. Therefore, two peptides encoded by the same gene exert contrasting effects on energy homeostasis via different receptors [13] .
Ghrelin, obestatin and CKD
Human data on ghrelin and CKD-PEW are inconclusive to date. Although ghrelin is degraded in the kidney, its levels are not uniformly increased in CKD patients [15] . Some studies with dialysis patients have demonstrated elevated ghrelin levels, whereas other studies have shown normal or even low ghrelin levels in CKD patients [16, 17] . A possible explanation for these seemingly contradicting findings is that only UAG levels were elevated in the CKD patients. For example, Gupta et al. [18] analyzed AG and UAG levels in 51 CKD and 15 hemodialysis (HD) patients using two separate site-specific assays for these hormones. The results demonstrated that UAG levels increased with declining estimated glomerular filtration rate (eGFR), whereas AG levels remained unchanged. In particular, increased UAG concentrations inversely correlated with eGFR with high accuracy.
In their recently published article in Pediatric Nephrology, Monzani and colleagues measured both UAG and obestatin and investigated their efficacy as potential biomarkers of PEW in CKD children [19] . Measurements of ghrelin (acylated and unacylated) and obestatin were compared between 110 children with CKD (42 on conservative treatment, 20 on HD, and 48 transplantation recipients) and 43 controls. The results showed that while AG concentrations did not differ between the patients and controls, UAG concentrations was significantly higher in the patients, notably in CKD-HD patients. Likewise, obestatin concentrations were significantly higher in CKD-HD patients than in the control subjects and in nondialysis CKD patients.
Monzani et al.'s study [19] provides some novel information concerning the possible role of the hormones that partially regulate food intake and energy homeostasis in CKD children. We believe that the special interest of this study lies in the fact that UAG, AG, and obestatin concentrations were, for the first time, measured separately in a considerable cohort of pediatric patients with CKD. As a result, the approach of these authors allowed confirmation of the hypothesis that UAG accounts for the excess of circulating ghrelin in pediatric CKD patients. In addition, there was an inverse correlation of UAG with eGFR, urea, body mass index (BMI)-standard deviation score (SDS), weight-SDS, and percentage fat-free mass, and a direct correlation of UAG with creatinine and urea as well as percentage fat-free mass. There was an inverse correlation of obestatin with eGFR and weight-SDS and a direct correlation with creatinine and urea. The authors were careful to account for possible confounding variables, such as gender, age, puberty, and BMI-SDS. Therefore, they were able to draw the conclusion that UAG and obestatin seem to be promising inverse indicators of nutritional status in children with CKD.
Regarding the treatment of PEW syndrome, it is important to point out the possible clinical implications of the findings of Monzani and colleagues [19] . Evidence to date has evaluated the orexigenic impact of AG pharmacology in patients with chronic disorders [20] . For example, a number of experimental studies have corroborated the potential of ghrelin and ghrelin analogues to increase food intake and body weight gain in cachectic patients with heart failure [21] , CKD [22] , and cancer [23] . Based on these positive preliminary results, human trials have further demonstrated enhancements of appetite and body mass with ghrelin analogue treatment in patients with anorexia nervosa [24] , renal failure [25] , heart failure [26] , chronic obstructive pulmonary disease [27] , and cancer [28] . However, the long-term safety and efficacy of ghrelin for the treatment of cachexia associated with chronic conditions has not been systematically investigated. Interestingly, in light of their findings, Monzani et al. [19] argue that a fundamental point in treatment of PEW syndrome in pediatric end-stage renal disease patients Bshould be the effective removal of anorexigenic molecules like UAG and obestatin, rather than the administration of AG^. This is an interesting though still speculative hypothesis that needs to be addressed by future studies.
Conclusion
The study by Monzani et al. [19] undoubtedly contributes to our knowledge concerning the peptides involved in pediatric CKD and PEW. The authors provide important data regarding UAG, AG, and obestatin concentrations in a considerable cohort of pediatric CKD patients, with important novel implications for biomarker discovery and therapeutic strategy. Further investigations are needed on the role of these hormones in the pathophysiology and treatment of complex nutritional disorders in pediatric CKD.
